VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The value of CAR-T cell therapy for the treatment of R/R multiple myeloma

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares some insights into the value of CAR-T cell therapy for the treatment of patients with relapsed/refractory (R/R) multiple myeloma, commenting on the impressive overall response rates (ORR) observed in heavily pre-treated patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter